AVECHO BIOTECHNOLOGY LIMITED — Capital/Financing Update 2021

Feb 7, 2021

Market Announcement

==> picture [33 x 50] intentionally omitted <==

8 February 2021

==> picture [451 x 5] intentionally omitted <==

Avecho Biotechnology Limited (ASX: AVE) – Trading Halt

Description

The securities of Avecho Biotechnology Limited (‘AVE’) will be placed in trading halt at the request of AVE, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 10 February 2021 or when the announcement is released to the market.

Issued by

Melissa Kostopoulos

Compliance Adviser, Listings Compliance (Melbourne)

Market Announcement 1/1 ASX Customer Service Centre 131 279 | asx.com.au

8 February 2021 ASX Limited

==> picture [77 x 35] intentionally omitted <==

==> picture [24 x 26] intentionally omitted <==

==> picture [22 x 35] intentionally omitted <==

==> picture [26 x 26] intentionally omitted <==

ASX Announcement

8 February 2021

ASX Market Announcements ASX Limited Level 4 525 Collins Street, Rialto, North Tower Melbourne VIC 3000

By email only: melissa.kostopoulos@asx.com.au tradinghaltsmelbourne@asx.com.au

Dear Melissa,

REQUEST FOR TRADING HALT

Avecho Biotechnology Limited (ASX: AVE) ( the Company ) requests an immediate halt to the trading of the Company’s ordinary shares quoted on the Australian Securities Exchange (ASX) in accordance with ASX Listing Rule 17.1.

The trading halt is requested pending the release of information by the Company to the market relating to a capital raise ( purpose ).

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

1. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make a material announcement to the market in relation to the stated purpose above.

2. The Company requests that the trading halt remains in place until the earlier of commencement of normal trading on Wednesday 10 February 2021, or when the announcement regarding the stated purpose is released to the market.

3. The Company expects to make the announcement to the market before the commencement of normal trading on Wednesday 10 February 2021.

4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

Please contact me if you require any further information concerning this matter.

Yours sincerely.

==> picture [84 x 29] intentionally omitted <==

Melanie Leydin Company Secretary

Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403 Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168

avecho.com.au

==> picture [77 x 35] intentionally omitted <==

==> picture [24 x 26] intentionally omitted <==

==> picture [22 x 35] intentionally omitted <==

==> picture [26 x 26] intentionally omitted <==

About Avecho

Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM® (Tocopherol Phosphate Mixture). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho’s major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market, including the recently announced application of TPM® to cannabinoids. The Company is also developing TPM[®] to enhance feed efficiency and health of livestock.

See more here - avecho.com.au

Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403 Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168

avecho.com.au